VIDEO: Multiple myeloma treatments evolve as access to new technology improves
C. Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses new drugs and developments in therapy for multiple myeloma.
“There is a lot of change going on,” Landgren said. “And I think that the myeloma field is almost changing every 6 months with the current pace and with access to all these new technologies.”
Landgren highlights three recent FDA approvals for the treatment of multiple myeloma – two monoclonal antibodies and an oral proteasome inhibitor.
“These new drugs, they target new mechanism of action in [multiple myeloma] that go beyond anything we currently have, and that makes it, of course, very exciting for patients who are refractory to available therapies,” he said.
Landgren also mentions how he envisions bundling these recently FDA-approved drugs in combination with previously available drugs.
“I think it is quite likely that we are going to end up in a situation where we are going to use four drugs for the newly-diagnosed patients with multiple myeloma and we probably can reach a complete response in … 80% or 90% of patients with these combinations,” he said.